. Author manuscript; available in PMC: 2020 Mar 1.

Published in final edited form as: Clin Pharmacol Ther. 2018 Oct 9;105(3):692–702. doi: 10.1002/cpt.1220

Table 3.

Final PK model estimates for median AUC_0–72 exposure to metabolites by dosing cohort.

	DSF (Disulfiram) RSE (%)^g	M1 (DDTC) RSE (%)^g	M2 (DDTC-Me) RSE (%)^g	M3 (DETC-MeSO) RSE (%)^g	M4 (Carbamathione) RSE (%)^g
Final PK median AUC_0–72 estimates (median and 2.5 to 97.5 percentile range)
500 mg group	3,186 (3,140 – 3,281)	2,826 (2,651 – 3,602)	2,309 (1,563 – 3,397)	1,563 (1,324 – 2,544)	4,295 (4,041 – 4,923)
1000 mg group	8,386 (7,419 – 12,861)	7,511 (4,974 – 14,886)	4,154 (3,416 – 6,000)	3,225 (2,102 – 5,383)	8,640 (7,232–19,379)
2000 mg group	22,331 (18,482 – 35,102)	20,362 (15,114 – 31,421)	7,048 (6,248 – 9,701)	8,643 (6,279 – 9,976)	25,167 (16,058–32,086)

Abbreviations: DSF = parent drug, disulfiram; M1 = metabolite 1; M2 = metabolite 2; M3 = metabolite 3; M4 = metabolite 4; DSF = disulfiram; DDTC = N,N-diethyldithiocarbamate; DDTC = diethyldithiocarbamate-methyl ester; DDTC-MeSO = S-methyl-N,N-diethylthiolcarbamate sulfoxide.